ALKEM LABORATORIES LTD.

NSE : ALKEMBSE : 539523ISIN CODE : INE540L01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE4940.20-58.8 (-1.18 %)
PREV CLOSE ( ) 4999.00
OPEN PRICE ( ) 4889.60
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 16861
TODAY'S LOW / HIGH ( )4849.30 5010.00
52 WK LOW / HIGH ( )3211.05 5519.1
NSE4942.00-62.2 (-1.24 %)
PREV CLOSE( ) 5004.20
OPEN PRICE ( ) 4935.00
BID PRICE (QTY) 4942.00 (95)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 427458
TODAY'S LOW / HIGH( ) 4820.05 5009.95
52 WK LOW / HIGH ( )3186.3 5520
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 08-08 1973
Management Info
Basudeo N Singh - Chairman Sandeep Singh - Managing Director
Registered Office

Address Alkem House,Senapati Bapat Marg,Lower Parel (West),
Mumbai,
Maharashtra-400013

Phone 022 3982 9999

Email investors@alkem.com / contact@alkem.com

Website www.alkemlabs.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS
28Mar USFDA concludes inspection at Alkem La
U.S Food and Drug Administration (USFDA) has concluded inspection at Alk..
28Mar Alkem Laboratories incorporates wholly
Alkem Laboratories has incorporated Wholly Owned Subsidiary (WOS) of the..
06Mar Alkem Laboratories informs about notic
Alkem Laboratories has informed that it attached the Postal Ballot Notic..
28Feb USFDA issues EIR for Alkem Laboratorie
U.S Food and Drug Administration (USFDA) has issued an Establishment Ins..
28Feb Alkem Laboratories informs about press
In furtherance to the intimation captioned ‘US FDA Inspection at Company..
Financials
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit5042.311344.7
Gross Profit 5343.8 13269.9
Operating Profit 6649.216432.4
Net Sales 24945.990545.5
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Abbott India (BSE)
 26946.00 (0.74%)
M.Cap (Rs. in Cr)57258.37
Sanofi India (BSE)
 8118.25 (2.06%)
M.Cap (Rs. in Cr)18696.83
Dr. Reddy's Lab (BSE)
 6155.15 (1.78%)
M.Cap (Rs. in Cr)102679.14
Divi's Lab (BSE)
 3436.75 (2.14%)
M.Cap (Rs. in Cr)91234.91
Glaxosmithkline Phar (BSE)
 1943.10 (3.26%)
M.Cap (Rs. in Cr)32917.29
Shareholding Pattern
PROMOTERS 56.74%
NON-INSTITUTION 18.86%
MUTUAL FUNDS/UTI 12.08%
FI/BANKS/INSURANCE 2.86%
GOVERNMENT 0%
FII 0%
ATTENTION INVESTORSKYCIPO
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.